<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: 18 patients with refractory <z:hpo ids='HP_0002384'>complex partial seizures</z:hpo> with or without secondary generalization resistant at common AED were studied </plain></SENT>
<SENT sid="1" pm="."><plain>They were treated in a open label study with felbamate for a 22 months period </plain></SENT>
<SENT sid="2" pm="."><plain>Felbamate monotherapy show a statistical significant improvement in the control of <z:hpo ids='HP_0001250'>seizures</z:hpo> in these patients versus CBZ therapy </plain></SENT>
<SENT sid="3" pm="."><plain>No severe side effects were reported specially <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0001399'>hepatic failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>At present, after 2 years, <z:hpo ids='HP_0000001'>all</z:hpo> the patients are still treated with felbamate </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (<z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo> and <z:hpo ids='HP_0002039'>anorexia</z:hpo>) and central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:hpo ids='HP_0002315'>headache</z:hpo>, sonnolence, <z:hpo ids='HP_0000651'>diplopia</z:hpo>, dizziness and <z:hpo ids='HP_0100785'>insomnia</z:hpo>) disturbances </plain></SENT>
<SENT sid="6" pm="."><plain>These adverse effects last, generally, for three weeks and allow to continue the treatment </plain></SENT>
</text></document>